Sorry, you need to enable JavaScript to visit this website.

Learn About STELARA® (ustekinumab) for Crohn's Disease | STELARA® (ustekinumab)

CHOOSE TO MOVE FORWARD
WITH STELARA®

Ready to take the next step toward symptom relief? Looking for a treatment option that could fit into your busy schedule? Your path to lasting remission could start when you talk to your doctor about STELARA®.

Caret down iconYou are encouraged to report negative side effects of prescription drugs to the FDA.

Rapid relief icon

RAPID RELIEF

The majority of patients who were treated with STELARA® and were new to or had not failed a biologic saw relief from their Crohn’s disease symptoms in as little as 6 weeks, with noticeable improvement in as little as 3 weeks* for some.

*Symptom improvement was measured differently at weeks 3 and 6.

Lasting remission icon

LASTING REMISSION

The majority of patients were in remission at 1 year after responding to the one‑time intravenous (IV) infusion dose and continuing on STELARA® treatment.

Clinical trials of STELARA® included patients who failed or were intolerant to other medications, including a biologic, prior to STELARA®. Individual results may vary. STELARA® is not for everyone. Only you and your doctor can decide if STELARA® is right for you.

STELARA® RESULTS

STELARA® results from week 0 to year 5

After 1 year, patients and healthcare providers knew that STELARA® was being used. This may have increased results. Individual results may vary. STELARA® is not for everyone. Only you and your doctor can decide if STELARA® is right for you.

LEARN ABOUT DOSING WITH STELARA®

IV infusion icon

Start with an IV infusion
ONE TIME

STELARA® treatment starts with a one-time IV infusion through a vein in your arm that provides the amount of medication based on your body weight and is administered by a medical professional in a comfortable setting. It takes at least 1 hour to receive the full dose of medicine.

Injection icon

Keep going with maintenance injections EVERY 2 MONTHS

After the one-time IV infusion, you will receive STELARA® as an injection under the skin (subcutaneous injection) every 8 weeks.

STELARA® is intended for use under the guidance and supervision of your doctor. If your doctor decides that you or a caregiver may give your injections of STELARA® at home, you should receive training on the right way to prepare and inject STELARA®.

THE STELARA® DOSING DIFFERENCE

First 52 weeks of therapy after starter doses

While these factors are important, there are additional considerations for selecting treatment. Please talk to your doctor about treatment options and what might be right for you.

This presentation is not intended to compare the safety and effectiveness of these treatments. Please refer to each product’s full Prescribing Information for recommended dosing and administration.

§Indicated trademark is registered trademark of its respective owner.

THE LEGACY OF STELARA®

Clinical research icon
20+ YEARS

of combined clinical research 
and 10+ years on the market 
across indications

United States icon
500,000+ PATIENTS

are estimated to have been treated with STELARA® for Crohn’s disease and other indications in the US||

Treatment icon
140,000+ PATIENTS

are estimated to have been treated with STELARA® for Crohn’s disease and ulcerative colitis in the US

||This is based on information licensed from IQVIA™: LAAD claims, NPA, DDD for the period 2009-2021 reflecting estimates of real-world activity and based on custom methodologies developed by Janssen. All rights reserved.

The estimated number of patients treated with STELARA® in the United States is 121,000+ for CD and 22,000+ for UC.

MEET 2 STELARA® CROHN’S DISEASE PATIENTS

What is STELARA® and how does it work?

  • STELARA® is a prescription biologic medicine
  • Many biologics are made from proteins, genes, or antibodies
  • Some biologics target enzymes or proteins that may cause inflammation—like the inflammation thought to cause Crohn’s disease symptoms

STELARA® works differently

There are many different naturally occurring proteins in the body that contribute to inflammation. Patients with Crohn’s disease are found to have elevated levels of two of these proteins, IL-12 and IL-23.

STELARA® is the only FDA-approved medicine that targets IL-12 and IL-23, which are thought to be associated with gastrointestinal inflammation in Crohn’s disease.

Play video button icon

Transcripts:

STELARA® SAFETY

Ask your doctor about the benefits and risks of STELARA®. Prescription medications, including STELARA®, have possible risks involved with treatment, so it’s important to discuss them with your doctor.

STELARA® is not for everyone; only your doctor can decide if it's right for you. STELARA® is a prescription medicine that affects your immune system. It can increase your chance of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition called posterior reversible encephalopathy syndrome.

These are not all the possible side effects of STELARA®.

Please read the Important Safety Information located at the bottom of the screen and the Medication Guide for STELARA® to learn more about these and other risks for STELARA®. Discuss any questions you have with your doctor.

In clinical studies, the most common side effects were:

  • nasal congestion, sore throat, and runny nose
  • upper respiratory infections
  • fever
  • headache
  • tiredness
  • itching
  • nausea and vomiting
  • redness at the injection site
  • vaginal yeast infections
  • urinary tract infections
  • sinus infection
  • bronchitis
  • diarrhea
  • stomach pain
  • joint pain

These are not all of the possible side effects of STELARA®. Call your doctor for medical advice about side effects.

You should not receive a live vaccine while taking STELARA®. Before receiving STELARA®, tell your doctor if you have recently received or are scheduled to receive an immunization (vaccine). Tell your doctor if anyone in your house needs a vaccine. The viruses used in some types of vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before taking STELARA® or one year after you stop taking STELARA®.

IS STELARA® RIGHT FOR YOU? ASK YOUR DOCTOR TODAY.

When it comes to getting control of your Crohn’s disease symptoms, you are your own best advocate. The road to remission starts with an open and honest conversation with your doctor.

Play video button icon

Transcripts:

" Your relationship with your doctor, your ability to communicate with one another, is as vital as your treatment plan itself.

STELARA® PATIENT BROCHURE

If you want to learn more about STELARA®, please download our patient brochure.

Once you and your doctor have decided STELARA® is right for you, STELARA withMe will help you find the resources you may need to get started and stay on track. We will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment more affordable.

STELARA withMe SAVINGS PROGRAM

IF YOU USE COMMERCIAL OR PRIVATE HEALTH INSURANCE TO PAY FOR YOUR MEDICATION

ELIGIBLE PATIENTS PAY $5 PER DOSE

  • Eligible patients using commercial or private insurance can save out-of-pocket medication costs for STELARA®
  • Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medication
  • Maximum program benefit per calendar year shall apply
  • Terms expire at the end of each calendar year and may change
  • Program does not cover the cost to give you your treatment
  • See program requirements

STELARA withMe is limited to education about STELARA®, its administration, and/or the condition it treats. It is not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.